Our mission is to engineer precision biologics that master both the “space” and “time” of disease. By leveraging our BBB RMT and Fc Heterodimerization platforms, we deliver therapies that precisely target the brain’s microenvironments and act within critical therapeutic windows. Our goal is to redefine treatment for neurodegeneration, glioblastoma, and other complex disorders through the development of selective, effective, and transformative therapies.

Beyond our pioneering CNS therapeutics, our portfolio features innovative programs such as MVP-523—a dual IL-12/23 blocker that modulates immune pathways implicated in inflammatory and autoimmune diseases—demonstrating our commitment to advancing targeted therapies across multiple disease areas.

We envision a future where no disease—neurological, oncological, or immunological—is untreatable. Our aspiration is to lead a new era in biotherapeutics by enabling drugs to cross the blood-brain barrier, engage targets with precision, and intervene at optimal moments, while expanding biologics to address urgent needs in other complex conditions.